)
Edge20 Feb 2026
Dollar General: The Rural Retailer Playbook
How Dollar General built a small-box empire across rural America, scaling value and convenience into one of retail's most durable business models.
Lite Strategy
Lite Strategy (LITS) investor relations material
Lite Strategy Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary17 Feb, 2026
Executive summary
Shifted strategic focus from oncology drug development to a dual strategy: digital asset treasury (Litecoin) and pre-clinical R&D in nononcology indications.
Deployed $100M PIPE proceeds into Litecoin (LTC) as a primary reserve asset, launching the Litecoin Treasury Strategy in August 2025.
Launched active treasury management by deploying covered call options on Litecoin holdings, generating $600,000 in gross premiums in the quarter.
Initiated a $25M share repurchase program in October 2025, funded by treasury operations, repurchasing 137,541 shares at $1.47 average price by December 2025.
Discontinued clinical development of voruciclib in oncology and ceased global development of zandelisib; now exploring out-licensing and sale opportunities.
Financial highlights
Net loss of $30.8M for the quarter ended December 31, 2025, compared to $2.7M in the prior year quarter.
Net loss of $34.4M for the six months ended December 31, 2025, versus $10.7M for the same period in 2024.
Operating expenses rose to $29.9M for the quarter, mainly due to a $26.5M loss from change in fair value of digital assets.
Generated $600,000 in cash from covered call options on LTC during the quarter.
Cash and cash equivalents at $8.8M and digital assets at $64.0M as of December 31, 2025.
Outlook and guidance
Sufficient liquidity (cash and digital assets) to fund operations for at least the next 12 months.
Future capital requirements depend on the scope of the Litecoin Treasury Strategy and ongoing R&D activities.
Plans to continue selective treasury strategies and execute the share repurchase program in the second half of fiscal 2026.
Evaluating potential strategic investments or partnerships to expand operations and increase stockholder value.
Future yield targets for LTC treasury?
Timeline for $25M share repurchase completion?
Strategic role of pharma assets?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Lite Strategy earnings date
Q3 202619 May, 2026
Lite Strategy
Next Lite Strategy earnings date
Q3 202619 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
MEI Pharma Inc, formerly known as Marshall Edwards Inc., is a clinical-stage pharmaceutical company focusing on developing innovative therapies for cancer treatment. The company's drug development focus includes pracinostat, an oral histone deacetylase inhibitor aimed at treating advanced hematological diseases such as myelodysplastic syndrome. Additionally, MEI Pharma is working on ME-344, a mitochondrial inhibitor for the treatment of HER2-negative breast cancer and solid tumors, and Zandelisib (ME-401), an oral PI3K delta inhibitor for relapsed or refractory B-cell malignancies. Another key drug candidate is Voruciclib, an oral and selective cyclin-dependent kinase (CDK) inhibitor intended for the treatment of acute myeloid leukemia (AML) and B-cell malignancies, being developed in agreement with Presage. It is headquartered in San Diego, California, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage